Welcome to our dedicated page for Artelo Biosciences news (Ticker: ARTL), a resource for investors and traders seeking the latest updates and insights on Artelo Biosciences stock.
Artelo Biosciences, Inc. develops clinical-stage therapeutics that modulate lipid-signaling pathways, including programs tied to the endocannabinoid system and fatty acid-binding proteins. Company news commonly covers pipeline updates for ART27.13 and ART26.12, including cancer anorexia-cachexia, neuropathic pain, glaucoma, dermatologic, neurological and other inflammation-related indications.
Recurring developments include FABP5 inhibitor research, peer-reviewed publications, collaborations using biological-data analysis, preclinical and clinical program disclosures, patent activity, and externally funded studies. Artelo news also includes capital-structure actions such as private placements, common stock and warrant offerings, and Nasdaq listing-compliance matters.
Artelo Biosciences has received a new U.S. patent covering ART12.11, its cocrystal solid form of CBD and TMP, providing intellectual property protection until December 10, 2038. This patent validates the company's strategy in developing novel CBD therapeutics aimed at major health issues like PTSD and inflammatory bowel disease. CEO Gregory D. Gorgas highlighted that the cocrystal approach could enhance drug properties, potentially improving efficacy and safety. Artelo is committed to advancing treatments targeting various diseases through their proprietary therapeutics.